BACKGROUND: Little is known about the association of cortical Aβ with depression and anxiety among cognitively normal (CN) elderly persons. METHODS: We conducted a cross-sectional study derived from the population-based Mayo Clinic Study of Aging in Olmsted County, Minnesota; involving CN persons aged ≥ 60 years that underwent PiB-PET scans and completed Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI). Cognitive diagnosis was made by an expert consensus panel. Participants were classified as having abnormal (≥1.4; PiB+) or normal PiB-PET (<1.4; PiB-) using a global cortical to cerebellar ratio. Multi-variable logistic regression analyses were performed to calculate odds ratios (OR) and 95% confidence intervals (95% CI) after adjusting for age and sex. RESULTS: Of 1,038 CN participants (53.1% males), 379 were PiB+. Each one point symptom increase in the BDI (OR = 1.03; 1.00-1.06) and BAI (OR = 1.04; 1.01-1.08) was associated with increased odds of PiB-PET+. The number of participants with BDI > 13 (clinical depression) was greater in the PiB-PET+ than PiB-PET- group but the difference was not significant (OR = 1.42; 0.83-2.43). Similarly, the number of participants with BAI > 10 (clinical anxiety) was greater in the PiB-PET+ than PiB-PET- group but the difference was not significant (OR = 1.77; 0.97-3.22). CONCLUSIONS: As expected, depression and anxiety levels were low in this community-dwelling sample, which likely reduced our statistical power. However, we observed an informative albeit weak association between increased BDI and BAI scores and elevated cortical amyloid deposition. This observation needs to be tested in a longitudinal cohort study.
BACKGROUND: Little is known about the association of cortical Aβ with depression and anxiety among cognitively normal (CN) elderly persons. METHODS: We conducted a cross-sectional study derived from the population-based Mayo Clinic Study of Aging in Olmsted County, Minnesota; involving CN persons aged ≥ 60 years that underwent PiB-PET scans and completed Beck Depression Inventory-II (BDI-II) and Beck Anxiety Inventory (BAI). Cognitive diagnosis was made by an expert consensus panel. Participants were classified as having abnormal (≥1.4; PiB+) or normal PiB-PET (<1.4; PiB-) using a global cortical to cerebellar ratio. Multi-variable logistic regression analyses were performed to calculate odds ratios (OR) and 95% confidence intervals (95% CI) after adjusting for age and sex. RESULTS: Of 1,038 CN participants (53.1% males), 379 were PiB+. Each one point symptom increase in the BDI (OR = 1.03; 1.00-1.06) and BAI (OR = 1.04; 1.01-1.08) was associated with increased odds of PiB-PET+. The number of participants with BDI > 13 (clinical depression) was greater in the PiB-PET+ than PiB-PET- group but the difference was not significant (OR = 1.42; 0.83-2.43). Similarly, the number of participants with BAI > 10 (clinical anxiety) was greater in the PiB-PET+ than PiB-PET- group but the difference was not significant (OR = 1.77; 0.97-3.22). CONCLUSIONS: As expected, depression and anxiety levels were low in this community-dwelling sample, which likely reduced our statistical power. However, we observed an informative albeit weak association between increased BDI and BAI scores and elevated cortical amyloid deposition. This observation needs to be tested in a longitudinal cohort study.
Authors: Gaël Chételat; Victor L Villemagne; Kerryn E Pike; Kathryn A Ellis; David Ames; Colin L Masters; Christopher C Rowe Journal: Neurodegener Dis Date: 2012-02-01 Impact factor: 2.977
Authors: John C Morris; Catherine M Roe; Elizabeth A Grant; Denise Head; Martha Storandt; Alison M Goate; Anne M Fagan; David M Holtzman; Mark A Mintun Journal: Arch Neurol Date: 2009-12
Authors: Anna Pink; Scott A Przybelski; Janina Krell-Roesch; Gorazd B Stokin; Rosebud O Roberts; Michelle M Mielke; Kathleen A Spangehl; David S Knopman; Clifford R Jack; Ronald C Petersen; Yonas E Geda Journal: J Neuropsychiatry Clin Neurosci Date: 2016-08-31 Impact factor: 2.198
Authors: Yonas E Geda; David S Knopman; David A Mrazek; Gregory A Jicha; Glenn E Smith; Selamawit Negash; Bradley F Boeve; Robert J Ivnik; Ronald C Petersen; V Shane Pankratz; Walter A Rocca Journal: Arch Neurol Date: 2006-03
Authors: Ronald C Petersen; Heather J Wiste; Stephen D Weigand; Walter A Rocca; Rosebud O Roberts; Michelle M Mielke; Val J Lowe; David S Knopman; Vernon S Pankratz; Mary M Machulda; Yonas E Geda; Clifford R Jack Journal: JAMA Neurol Date: 2016-01 Impact factor: 18.302
Authors: Yonas E Geda; Rosebud O Roberts; David S Knopman; Ronald C Petersen; Teresa J H Christianson; Vernon S Pankratz; Glenn E Smith; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Walter A Rocca Journal: Arch Gen Psychiatry Date: 2008-10
Authors: Leslie M Shaw; Magdalena Korecka; Christopher M Clark; Virginia M-Y Lee; John Q Trojanowski Journal: Nat Rev Drug Discov Date: 2007-03-09 Impact factor: 84.694
Authors: Antonio Terracciano; Murat Bilgel; Damaris Aschwanden; Martina Luchetti; Yannick Stephan; Abhay R Moghekar; Dean F Wong; Luigi Ferrucci; Angelina R Sutin; Susan M Resnick Journal: Biol Psychiatry Date: 2021-09-03 Impact factor: 12.810
Authors: Janina Krell-Roesch; Maria Vassilaki; Michelle M Mielke; Walter K Kremers; Val J Lowe; Prashanthi Vemuri; Mary M Machulda; Teresa J Christianson; Jeremy A Syrjanen; Gorazd B Stokin; Lesley M Butler; Martin Traber; Clifford R Jack; David S Knopman; Rosebud O Roberts; Ronald C Petersen; Yonas E Geda Journal: Transl Psychiatry Date: 2019-03-28 Impact factor: 6.222
Authors: Janina Krell-Roesch; Jeremy A Syrjanen; Martin Rakusa; Prashanthi Vemuri; Mary M Machulda; Walter K Kremers; Michelle M Mielke; Val J Lowe; Clifford R Jack; David S Knopman; Gorazd B Stokin; Ronald C Petersen; Maria Vassilaki; Yonas E Geda Journal: J Neuropsychiatry Clin Neurosci Date: 2020-10-22 Impact factor: 2.198